{
  "docId": "019de515-e1f4-739b-a349-913fc7c75e72",
  "docSlug": "3b70dadd72cd7c3c7226b36c1da9b327",
  "documentTitle": "Allurion | SPAC Presentation Deck | 25 slides",
  "authorId": "allurion",
  "authorName": "Allurion",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 25,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "overcrowded",
  "nDataPoints": 100,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de515-e1f4-739b-a349-913fc7c75e72/8",
  "deckHref": "/decks/019de515-e1f4-739b-a349-913fc7c75e72",
  "deckJsonHref": "/decks/019de515-e1f4-739b-a349-913fc7c75e72.json",
  "deckAnchorHref": "/decks/019de515-e1f4-739b-a349-913fc7c75e72#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.41,
        "w": 0.47,
        "x": 0.06,
        "y": 0.148
      },
      "kind": "chart",
      "text": "Obesity: $50B+ Revenue Market by 2030\nUS revenues\nEx-US revenues\nHigh-efficacy patient share",
      "attrs": {
        "series": [
          "US revenues",
          "Ex-US revenues",
          "High-efficacy patient share"
        ],
        "chart_type": "stacked bar chart with line",
        "x_axis_labels": "2024, 2025, 2026, 2027, 2028, 2029, 2030",
        "y_axis_labels": "$bn (0-60), % (0-10)"
      },
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47643623-1f35-48f3-930a-b047cae3187b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.41,
        "w": 0.42,
        "x": 0.53,
        "y": 0.148
      },
      "kind": "chart",
      "text": "GLP-1s Made Obesity Mainstream\nDiabetes drug for weight loss: (Worldwide)\nSemaglutide: (Worldwide)\nLaunch of Ozempic (semaglutide in diabetes)\nLaunch of Wegovy (semaglutide in obesity)\nHALO EFFECT",
      "attrs": {
        "series": [
          "Diabetes drug for weight loss: (Worldwide)",
          "Semaglutide: (Worldwide)"
        ],
        "chart_type": "line chart",
        "x_axis_labels": "Jan-13 to Jan-22",
        "y_axis_labels": "0-100"
      },
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "319cd24f-eb01-4c4a-adc8-815386425b4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.08,
        "y": 0.62
      },
      "kind": "list",
      "text": "Saxenda\nliraglutide injection 3mg\n2015",
      "attrs": {},
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b1372b1-5eae-4dca-aa8e-bea851b191c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.8,
        "y": 0.62
      },
      "kind": "list",
      "text": "mounjaro™\n(tirzepatide) injection\n2022",
      "attrs": {},
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51846683-3a60-4d34-8cec-ef896d033a3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.44,
        "y": 0.62
      },
      "kind": "list",
      "text": "RYBELSUS\nsemaglutide tablets\n2019",
      "attrs": {},
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ef0dfb5-2ca1-467a-b786-fe3b6f991bed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.26,
        "y": 0.62
      },
      "kind": "list",
      "text": "OZEMPIC\nsemaglutide injection 0.5mg, 1mg, 2mg\n2017",
      "attrs": {},
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8810825b-3180-4193-81cd-081c20b25f51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.62,
        "y": 0.62
      },
      "kind": "list",
      "text": "wegovy\nsemaglutide injection 2.4 mg\n2021",
      "attrs": {},
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91b263de-9517-4720-b057-2ffa1b0d4a19",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.45,
        "x": 0.029,
        "y": 0.969
      },
      "kind": "source-note",
      "text": "Sources: Morgan Stanley, \"Unlocking the Obesity Challenge: a >$50BN Market\"",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f58a7619-0f4a-422f-83e1-8be9ad47a47f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.87,
        "x": 0.078,
        "y": 0.045
      },
      "kind": "title",
      "text": "The Time is Now: GLP-1 Drugs Created Unprecedented Interest in Weight Loss and Unlocked a a $50 Billion Revenue Opportunity",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e76c4a3-4a6f-49ff-bc6b-544660677f8c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "db0c5598-d3ff-4b9a-ad79-345eacb370af",
      "evidence": "The slide presents a clear problem and opportunity, grabbing the audience's attention and interest.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "71296a98-68bf-47f9-bf2e-69246aa38cfa",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 6-9 present the problem statement and challenges with current solutions",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e850bac4-aef0-4f3b-bd2d-0b6e91fa1886",
      "evidence": "The deck presents the limitations and challenges of current solutions, implying the cost of inaction",
      "position": 0,
      "objective": "What is the cost of not addressing obesity?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 8,
      "from": 8,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "2e2d5ca7-dbce-42d8-8f84-c992b9728b05",
      "evidence": "Slide 8 presents the GLP-1 drugs and the $50 billion revenue opportunity",
      "position": 1,
      "objective": "Why is now the right time for Allurion's solution?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}